Name: Phenylephrine HCl
Brand: Selleck Chemicals
SKU: S2569
Availability: InStock
Rating: 5 (10 reviews)

Jump to

Quality Control

Batch: Purity: 99.95%

99.95

Related Targets	CXCR Hedgehog/Smoothened PKA AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas GPR
Other Adrenergic Receptor Inhibitors	ICI 118551 Hydrochloride (Zenidolol) L755507 Yohimbine HCl Atipamezole Higenamine hydrochloride Noradrenaline bitartrate monohydrate Fenoterol hydrobromide Medetomidine HCl Isoprenaline L-Adrenaline

Solubility

In vitro
Batch:

DMSO : 41 mg/mL (201.3 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 41 mg/mL

Ethanol : 41 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.050mg/ml (10.07mM)	Taking the 1 mL working solution as an example, add 50 μL of 41 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.050mg/ml (10.07mM)	Taking the 1 mL working solution as an example, add 50 μL of 41 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	203.67	Formula	C₉H₁₃NO₂.HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	61-76-7	Download SDF		Storage of Stock Solutions	Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.
Synonyms	NCI-C55641 HCl,(R)-(-)-Phenylephrine hydrochloride, L-Phenylephrine hydrochloride			SMILES	CNCC(C1=CC(=CC=C1)O)O.Cl

Read more about storage stability CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	α1-adrenergic receptor
In vitro	Phenylephrine causes a rapid translocation of PKC-epsilon (EC50 = 0.9 mM) but the proportion lost from the soluble fraction is less than with ET-1. Phenylephrine at pCa 7 causes a dose-dependent increase in contractile force of the hyperpermeable cells, which is reversible on addition of phentolamine. Phenylephrine also protects cardiomyocytes against subsequent 24 h treatment with hypoxia and serum deprivation. Phenylephrine prevents the down-regulation of Bcl-2 and Bcl-X mRNA/protein and induces hypertrophic growth. Phenylephrine-mediated protection is abrogated by the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor wortmannin and is mimicked by the caspase-9 peptidic inhibitor LEHD-fmk. Phenylephrine stimulates phosphoinositide (PI) hydrolysis, cell growth, and expression of several genes [e.g., atrial natriuretic factor (ANF)] often associated with cardiac hypertrophy. Phenylephrine (1 礛) markedly potentiates HGF-induced hepatocyte DNA synthesis and proliferation. Phenylephrine (10 mM) reversibly increases I(Ca,L) (51.3%; n = 40) and shifted peak I(Ca,L) activation voltage by -10 mV. Phenylephrine also increases local, subsarcolemmal SR Ca²⁺ release via IP3-dependent signaling. Phenylephrin-induced NOi release requires stimulation of both PI-3K/Akt and IP3-dependent Ca²⁺ signaling. Phenylephrine-induced NOi release is inhibited by each of 1 mM prazocin, 10 mM L-NIO, 10 mM W-7, 10 mM LY294002, 2 mM H-89, 10 mM ryanodine, 5 mM thapsigargin, 2 mM 2-APB or 10 mM xestospongin C.
References	[1] https://pubmed.ncbi.nlm.nih.gov/7806510/ [2] https://pubmed.ncbi.nlm.nih.gov/1558185/ [3] https://pubmed.ncbi.nlm.nih.gov/11042672/ [4] https://pubmed.ncbi.nlm.nih.gov/8383460/ [5] https://pubmed.ncbi.nlm.nih.gov/9316820/ [6] https://pubmed.ncbi.nlm.nih.gov/15946966/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-02-13)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06677970	RECRUITING	Acute Ischemic Stroke	Yonsei University	2024-10-01	PHASE3
NCT06802224	RECRUITING	Anesthesia; Surgery With General Anesthesia; Noncardiac Surgery; Hypotension During Surgery; Acute Kidney Injury (AKI); Myocardial Injury After Noncardiac Surgery (MINS); Vasopressor	University of California, San Francisco	2025-04-01	PHASE4
NCT01731444	RECRUITING	Blood Loss, Surgical	University of Manitoba	2014-12-01	PHASE1
NCT07796282	NOT_YET_RECRUITING	Spine Surgery; Intraoperative Hypotension; Tissue Perfusion	Mayo Clinic	2026-09	PHASE4
NCT06083948	RECRUITING	Hypotension	University of Aarhus	2023-12-20	PHASE2; PHASE3
NCT05997732	RECRUITING	Vasoconstriction; Vasodilation	University of Alberta	2023-10-31	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Phenylephrine HCl Adrenergic Receptor agonist

Chemical Structure

Molecular Weight: 203.67